Intestinal ischemia-reperfusion (IR) is a frequently occurring phenomenon during abdominal and thoracic vascular surgery, small bowel transplantation, hemorrhagic shock, and surgery using cardiopulmonary bypass, carrying high morbidity and mortality.Ambroxol hydrochloride (C13 H18 Br2 N2 O) is an active N-desmethyl metabolite of bromhexine hydrochloride,Ambroxol is indicated as "secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. Aim: The present study was designed to evaluate the effect of ambroxol on Experimentally induced acute organ oxidative stress in form of remote organ injury including kidney and heart after intestinal ischemia-reperfusion. Materials and methods:Animals were classified into,: normal control group, Intestinal I/R with no treated control group( Intestinal I/R was induced by mesenteric artery ligation),Ambroxol pre-treated intestinal ischemia-reperfusion group (35mg per kg ),Ambroxol pre-treated intestinal ischemia-reperfusion group (70mg per kg ),Ambroxol pre-treated intestinal ischemia-reperfusion group(140mg per kg ). Results: Ambroxol reduced MDA level in heart and kidney significantly when compared to Intestinal I/R with no medication group. It also improved cardiac troponin and, kidney functions (urea and creatinine) and histopathological affection when compared to Intestinal I/R with no medication group. Conclusively: In this study ambroxol had anti oxidative and anti-inflammatory effect. Recommendation:Ambroxol could have a protective effect against Intestinal I/ R . |
